Repligen: Ongoing Bioprocessing Market Recovery

I assigned a ‘buy’ rating to Repligen ( RGEN ) in July 2024, highlighting its strong filtration and weak growth in China. Since then, the stock price has surged by more than 14%. I believe Repligen’s business will gradually recover in FY25, supported byMore than 15 years of professional investment experience in global equities across all sectors. My investment style is fundamental, bottom-up, long-term, and quality growth-oriented. I am seeking companies specializing in niche markets, with strong growth pot ...